News
PULM
6.56
+39.57%
1.86
Pulmatrix Shares Hit 52-Week High After News of Merger Deal
Dow Jones · 1d ago
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
Barchart · 1d ago
Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders
Barchart · 2d ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders
Barchart · 2d ago
Pulmatrix Shares Surge on Merger with Cullgen
Dow Jones · 2d ago
Pulmatrix trading resumes
TipRanks · 2d ago
Pulmatrix and Cullgen Announce Strategic Merger Agreement
TipRanks · 2d ago
Cullgen to Absorb Pulmatrix, Join Nasdaq
Dow Jones · 2d ago
Pulmatrix announces merger agreement with Cullgen
TipRanks · 2d ago
Pulmatrix And Cullgen Announce Proposed Merger; Pre-Merger Pulmatrix Stockholers To Own ~3.6% Of Combined Company; Pre-Merger Cullgen Stockholders To Own ~96.4% Of Combined Company Under Name Cullgen
Benzinga · 2d ago
BRIEF-Pulmatrix And Cullgen Announce Proposed Merger
Reuters · 2d ago
*Pulmatrix: Pulmatrix Stockholders Will Receive Special Cash Div to Extent That Pulmatrix's Net Cash at Closing Exceeds $2.5M, Subject to Certain Adjustments >PULM
Dow Jones · 2d ago
*Pulmatrix: Combined Co Will Operate Under Name Cullgen Inc. and Trade on Nasdaq Cap Market >PULM
Dow Jones · 2d ago
Press Release: Pulmatrix and Cullgen Announce -2-
Dow Jones · 2d ago
Press Release: Pulmatrix and Cullgen Announce Proposed Merger
Dow Jones · 2d ago
Pulmatrix trading halted, news pending
TipRanks · 2d ago
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders
Barchart · 2d ago
Weekly Report: what happened at PULM last week (1104-1108)?
Weekly Report · 4d ago
Based on the provided financial report articles, I generated the title for the article: **"PULM, Inc. Quarterly Report (10-Q) for the period ended September 30, 2024"** Please note that the title may not be exact, as the provided text appears to be a financial report in XBRL format, which is a machine-readable format used for financial reporting. The title may require some manual editing to accurately reflect the content of the report.
Press release · 11/08 21:57
Pulmatrix GAAP EPS of -$0.71, revenue of $0.37M
Seeking Alpha · 11/08 17:14
More
Webull provides a variety of real-time PULM stock news. You can receive the latest news about Pulmatrix through multiple platforms. This information may help you make smarter investment decisions.
About PULM
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.